SEC Filing Summary for Q32 Bio Inc.

This filing details stock transactions by Violette Shelia M., Chief Scientific Officer of Q32 Bio Inc. On July 16, 2026, Ms. Violette acquired 37,500 shares of Common Stock under a performance-based restricted stock unit (PSU) grant. These PSUs vested upon the achievement of a financing condition, with vesting also subject to continued service over three years. Following this transaction, Ms. Violette directly owns 130,569 shares. Additionally, 36,277 shares are held indirectly through Violette Holdings LLC, of which Ms. Violette is a manager. The filing also notes a $0.0 price per share for the acquired shares, consistent with the nature of the PSU vesting.